{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:24:05Z","timestamp":1781706245047,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PD\u20101 or BRAF + MEK inhibition is considered the current gold standard in adjuvant melanoma therapy. Little is known if, after the recurrence of the disease and surgery, a second course of adjuvant therapy might be beneficial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter, retrospective study investigating a second course of adjuvant therapy after recurrence and surgery in stage III\u2013IV melanoma patients. Patients received nivolumab (NIV), pembrolizumab (PEM) or dabrafenib plus trametinib (D + T) between 01\/2017 and 10\/2021. The primary endpoint was 12\u2010month recurrence\u2010free survival (RFS2). Further analyses included descriptive and correlative statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty\u2010six patients from 22 centers in Germany, Austria and Switzerland were included. Thirty\u2010two patients received D\u2009+\u2009T as second\u2010course adjuvant therapy, 9 patients received PEM and 25 patients received NIV. Recurrence\u2010free survival for the second\u2010course adjuvant treatment (RFS2) was assessed after 12 and 24\u2009months and showed a superiority of adjuvant BRAF + MEK over PD\u20101 therapy (12\u2010months RFS2: 90.6% vs. 70.6%, HR 4.226 [95% CI 1.154\u201315.48];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030; 24\u2010months RFS2 71.9% vs. 52.9%, HR 3.154 [95% CI 1.374\u20137.242];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). There was no significant decrease in OS with either BRAF + MEK or PD\u20101 treatment (12\u2010months OS: 100% both, 24\u2010months OS: 100% vs. 93.8%).\n                    <\/jats:p>\n                    <jats:p>\n                      Furthermore, therapy sequences were investigated. For better comparability, only BRAF V600 mutated patients were assessed: RFS2 was significantly better for patients with a class switch from PD\u20101 to BRAF + MEK compared to BRAF + MEK to PD\u20101 (HR 4.401 (1.04\u201318.63),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044). No new safety signals were detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the investigated cohort, a second course of adjuvant melanoma treatment is feasible and provides similar RFS compared to an initial course of adjuvant therapy using BRAF + MEK inhibitors; however, RFS2 is reduced for PD\u20101 antibodies. In addition, both treatments were convincing with a 24\u2010month OS of almost 100%. Switching from adjuvant PD\u20101 to BRAF + MEK treatment provided better overall RFS compared to switching from adjuvant BRAF + MEK to PD\u20101 treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.20708","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T09:28:51Z","timestamp":1746610131000},"page":"1987-1996","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Switching PD\u20101 to BRAF + MEK inhibition improves recurrence\u2010free survival in patients receiving a second course of adjuvant melanoma therapy"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4691-513X","authenticated-orcid":false,"given":"Katharina","family":"Schumann","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK) Technical University of Munich  Munich Germany"},{"name":"Department for Phlebology and Venerology Artemed Hospital  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Christian","family":"Klespe","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology University Hospital RWTH Aachen  Aachen Germany"},{"name":"Department of Dermatology and Venereology University Hospital Cologne  Cologne Germany"},{"name":"Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD)  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Mauch","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology University Hospital Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[{"name":"Department for Dermatology and Allergology Clinic Bremen Ost  Bremen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schultheis","sequence":"additional","affiliation":[{"name":"Department for Dermatology Johannes Gutenberg\u2010University Mainz  Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevil","family":"B\u00f6rger","sequence":"additional","affiliation":[{"name":"Department for Dermatology University Hospital Kassel  Kassel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9504-4281","authenticated-orcid":false,"given":"Alexander","family":"Thiem","sequence":"additional","affiliation":[{"name":"Clinic and Policlinic for Dermatology and Venereology University Medical Center Rostock  Rostock Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Emmert","sequence":"additional","affiliation":[{"name":"Clinic and Policlinic for Dermatology and Venereology University Medical Center Rostock  Rostock Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Hoellwerth","sequence":"additional","affiliation":[{"name":"Department for Dermatology and Allergology Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"K\u00f6lblinger","sequence":"additional","affiliation":[{"name":"Department for Dermatology and Allergology Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department for Dermatology, Venereology and Allergology Medical University Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department for Dermatology, Venereology and Allergology Medical University Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Richtig","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Medical University Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2478-2951","authenticated-orcid":false,"given":"Wiebke K.","family":"Peitsch","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Vivantes Skin Cancer Center  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Harth","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Vivantes Skin Cancer Center  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Zenderowski","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Regensburg  Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-0633","authenticated-orcid":false,"given":"Andreas Dominik","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Magdeburg  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1651-7114","authenticated-orcid":false,"given":"Miriam","family":"Mengoni","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Magdeburg  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Dermatology Clinic University Hospital Zurich and University of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mangana","sequence":"additional","affiliation":[{"name":"Dermatology Clinic University Hospital Zurich and University of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9202-0073","authenticated-orcid":false,"given":"Lara Valeska","family":"Maul","sequence":"additional","affiliation":[{"name":"Dermatology Clinic University Hospital Zurich and University of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mei\u00df","sequence":"additional","affiliation":[{"name":"Department for Dermatology and Venereology Medical Center \u2013 University of Freiburg, Faculty of Medicine  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Rappersberger","sequence":"additional","affiliation":[{"name":"Department for Dermatology Clinic Landstra\u00dfe  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-4464","authenticated-orcid":false,"given":"Oana Diana","family":"Persa","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK) Technical University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilo","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK) Technical University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Posch","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK) Technical University of Munich  Munich Germany"},{"name":"Faculty of Medicine Sigmund Freud University Vienna  Vienna Austria"},{"name":"Department for Dermatology, Clinic Hietzing Vienna Healthcare Group  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"issue":"9","key":"e_1_2_15_3_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for melanoma","volume":"15","author":"Eggermont AMM","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_2_15_4_1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF).Diagnostik Therapie und Nachsorge des Melanoms Langversion 3.3 AWMF Registernummer: 032\/024OL.2020http:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/melanom\/(Accessed 9 Feb 2024)."},{"issue":"1","key":"e_1_2_15_5_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter SM","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"e_1_2_15_6_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CCO.0000000000000432","article-title":"Update on adjuvant melanoma therapy","volume":"30","author":"Dimitriou F","year":"2018","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"e_1_2_15_7_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325\u2010MG\/KEYNOTE\u2010054): distant metastasis\u2010free survival results from a double\u2010blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont AMM","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"e_1_2_15_8_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)\u2010mutant, stage III melanoma (COMBI\u2010AD): exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"Dummer R","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"e_1_2_15_9_1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2010C and stage IV melanoma (CheckMate 238): 4\u2010year results from a multicentre, double\u2010blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto PA","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"e_1_2_15_10_1","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/annonc\/mdz221","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K\u2010mutant melanoma: long\u2010term survival and safety analysis of a phase 3 study","volume":"30","author":"Long GV","year":"2019","journal-title":"Ann Oncol"},{"issue":"10105","key":"e_1_2_15_11_1","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open\u2010label phase 3 study (KEYNOTE\u2010006)","volume":"390","author":"Schachter J","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"e_1_2_15_12_1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE\u2010006): post\u2010hoc 5\u2010year results from an open\u2010label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert C","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"e_1_2_15_13_1","article-title":"Progression\/recurrence\u2010free survival 2 in adjuvant melanoma","volume":"1","author":"Augustin RC","year":"2022","journal-title":"N Engl J Med Evid"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology11030422"},{"issue":"10","key":"e_1_2_15_15_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102319","article-title":"Factors influencing the adjuvant therapy decision: results of a real\u2010world multicenter data analysis of 904 melanoma patients","volume":"13","author":"Lodde G","year":"2021","journal-title":"Cancers (Basel)"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14511"},{"issue":"5","key":"e_1_2_15_17_1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/jdv.18779","article-title":"Real\u2010world outcomes using PD\u20101 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland","volume":"37","author":"Schumann K","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_18_1","volume-title":"Melanom (\u00dcbersicht) C43","author":"Altmeyer P"},{"issue":"10","key":"e_1_2_15_19_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102870","article-title":"Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy","volume":"12","author":"Falcone I","year":"2020","journal-title":"Cancers (Basel)"},{"key":"e_1_2_15_20_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.phrs.2017.07.006","article-title":"Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance","volume":"123","author":"Pulluri B","year":"2017","journal-title":"Pharmacol Res"},{"issue":"2","key":"e_1_2_15_21_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF\u2010mutant melanoma: the DREAMseq trial\u2010ECOG\u2010ACRIN EA6134","volume":"41","author":"Atkins MB","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:41:35Z","timestamp":1763116895000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/jdv.20708"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20708","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"2024-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}